X
Thursday, July 3, 2025
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Improving Approach of UK Through Future Clinical Trials Bill

Content Team by Content Team
3rd November 2023
in Clinical Trials, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The Policy Exchange has come up with a report that highlights the potential benefits of The Future Clinical Trials Bill when it comes to improving UK’s approach in case of establishing and regulating clinical trials.

The new bill is one of several proposed policies that will be executed under the new legislative programme, which will be presented in the final session of this Parliament.

Future clinical trials bill offers several benefits

The main idea of the bill is to enhance patient engagement and also prioritise safety in clinical trials, while at the same time promoting a better flexible regulatory approach, as stated by the author. If this goal gets accomplished, it would enhance UK’s competitiveness as a prominent global destination in case of conducting trials.

As per Iain Mansfield, the author of the report and who also happens to be the Director of Research and Head of Education and Science at Policy Exchange, the Future Clinical Trials Bill is crucial as it addresses the existing challenges that limit the conduct of clinical trials throughout the UK. To be able to successfully deliver these trials, certain actions must be taken, like improving clinical trial set-up, design, as well as regulation, with a focus on achieving faster as well as more flexible processes.

Mansfield specified that UK’s approach has always been regarded as slow and this study was conducted by the Association of the British Pharmaceutical Industry- ABPI in 2022. The study revealed that between 2018 to 2020, there was a almost one-month rise in the average time it took for a participant in a trial to receive their first dose after applying for regulatory approval.

Mansfield pointed out that Spain has made substantial advances in recent years. This progress can be attributed to the introduction of legislation that enforces strict timelines for approval. It is well to be noted that within one year of the legislation being implemented, the average timeframes for setting up trials were reduced by 15%.

Mansfield provided a comprehensive list of the key components outlined in the Future Clinical Trials Bill, such as these:

  • The legislation aims to update the Medicines for Human Use (Clinical Trials) Regulations 2004, which happen to be based on the EU Clinical Trials Directive.
  • There are several provisions that can be implemented to ensure greater transparency.
  • To register trials, it is necessary to go through the Health Research Authority, which then proceeds to register the trials with the ISRCTN Registry, which is the primary and internationally recognised clinical trial registry recognised by the WHO.
  • It is necessary to publish a summary of the trial results within twelve months after its completion in order to promote future participation. This is only applicable if a deferral has been agreed upon.
  • The National Institute for Health and Care Research (NIHR) should be mandated to collect and publish monthly reports on NHS clinical trial activity nationwide. This activity aims to consolidate the relevant data sets collected by both the MHRA and the HRA.

Regulatory pragmatism in the context of clinical trials

A new time limit of sixty days will be introduced for trial participants to answer Requests for Further Information- RFI from the MHRA or Research Ethics Committee- REC. According to the report, this would allow sponsors enough time to prepare responses that meet the requirements of regulators.

The report acknowledged that the bill would implement a notification scheme for low intervention trials and would eliminate the need to report individual Suspected Unexpected Serious Adverse Reactions (SUSARs) to all trial investigators.

According to Mansfield, the provisions of the Future Clinical Trials Bill will require transparent trial registration and help expedite the approval process.

Previous Post

Pharma Packaging Market In Europe To Hit $35bn Come 2028

Next Post

Industry 5.0 Has Plenty To Offer To Pharma Manufacturing

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Developing Pharma Skills With Life Sci For Growth Initiative

Industry 5.0 Has Plenty To Offer To Pharma Manufacturing

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Notifications